References (Supplied by CrossRef)
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030
Wild et al.
Diabetes Care 2004
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Vos et al.
Nephropathy in patients with type 2 diabetes mellitus
Ritz et al.
N Engl J Med 1999
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
National Kidney Foundation et al.
Am J Kidney Dis 2012
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease
Strippoli et al.
Cochrane Database Syst Rev 2006
Should evidence-based proof of drug efficacy be extrapolated to a ‘class of agents’?
Furberg et al.
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
Mogensen et al.
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy
Bakris et al.
Kidney Int 2008
Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy
Ogawa et al.
Hypertens Res 2007
Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease
Kunz et al.
Ann Intern Med 2008
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials
Maione et al.
Nephrol Dial Transplant 2011